StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30537% above fair value
$70.07+0.85 (+1.23%)

Close on Nov 17, 2026Market cap $7.57BP/E 166.8Yield –

Corcept Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Corcept Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $6.41M, down 93.7% year over year. For fiscal 2025 it was $44.80M, down 67.3% from the year before. The highest annual figure on record is $136.95M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.80M-67.3%
FY2024Dec 31, 2024$136.95M+27.7%
FY2023Dec 31, 2023$107.28M-4.8%
FY2022Dec 31, 2022$112.63M-9.5%
FY2021Dec 31, 2021$124.48M-2.9%
FY2020Dec 31, 2020$128.20M+14.9%
FY2019Dec 31, 2019$111.61M+24.7%
FY2018Dec 31, 2018$89.50M+69.3%
FY2017Dec 31, 2017$52.86M+419.3%
FY2016Dec 31, 2016$10.18M–
FY2015Dec 31, 2015-$3.44M–
FY2014Dec 31, 2014-$27.62M–
FY2013Dec 31, 2013-$41.50M–
FY2012Dec 31, 2012-$36.27M–
FY2011Dec 31, 2011-$32.33M–
FY2010Dec 31, 2010-$27.44M–
FY2009Dec 31, 2009-$20.25M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$41.30M+54.8%
Q1 FY2026Mar 31, 2026-$49.60M-1552.0%
Q4 FY2025Dec 31, 2025$4.49M-82.2%
Q3 FY2025Sep 30, 2025$10.22M-78.1%
Q2 FY2025Jun 30, 2025$26.68M-25.1%
Q1 FY2025Mar 31, 2025$3.42M-88.4%
Q4 FY2024Dec 31, 2024$25.26M-20.2%
Q3 FY2024Sep 30, 2024$46.60M+49.5%
Q2 FY2024Jun 30, 2024$35.59M+20.3%
Q1 FY2024Mar 31, 2024$29.50M+98.6%
Q4 FY2023Dec 31, 2023$31.67M+40.8%
Q3 FY2023Sep 30, 2023$31.18M-2.4%
Q2 FY2023Jun 30, 2023$29.58M-5.9%
Q1 FY2023Mar 31, 2023$14.85M-44.5%
Q4 FY2022Dec 31, 2022$22.50M-38.6%
Q3 FY2022Sep 30, 2022$31.93M-11.9%
Q2 FY2022Jun 30, 2022$31.43M-1.6%
Q1 FY2022Mar 31, 2022$26.77M+36.3%
Q4 FY2021Dec 31, 2021$36.66M+20.2%
Q3 FY2021Sep 30, 2021$36.23M+46.6%
Q2 FY2021Jun 30, 2021$31.94M-9.4%
Q1 FY2021Mar 31, 2021$19.64M-47.9%
Q4 FY2020Dec 31, 2020$30.51M-12.9%
Q3 FY2020Sep 30, 2020$24.72M-25.1%
Q2 FY2020Jun 30, 2020$35.26M+43.1%
Q1 FY2020Mar 31, 2020$37.71M+98.9%
Q4 FY2019Dec 31, 2019$35.02M+40.6%
Q3 FY2019Sep 30, 2019$33.00M+43.7%
Q2 FY2019Jun 30, 2019$24.63M+19.4%
Q1 FY2019Mar 31, 2019$18.96M-9.7%
Q4 FY2018Dec 31, 2018$24.90M+14.8%
Q3 FY2018Sep 30, 2018$22.97M+68.6%
Q2 FY2018Jun 30, 2018$20.63M+61.3%
Q1 FY2018Mar 31, 2018$21.00M+342.9%
Q4 FY2017Dec 31, 2017$21.70M+333.3%
Q3 FY2017Sep 30, 2017$13.62M+343.5%
Q2 FY2017Jun 30, 2017$12.80M–
Q1 FY2017Mar 31, 2017$4.74M–
Q4 FY2016Dec 31, 2016$5.01M–
Q3 FY2016Sep 30, 2016$3.07M–

More Corcept Therapeutics figures

See a number that looks wrong?